1. Pink Sheet
  2. >>Market Access

Blow For Seagen As England Rejects Funding For Advanced Breast Cancer Drug Tukysa

 
• By Neena Brizmohun

England’s health technology assessment body said it would continue to work with Seagen to address the reasons why its newly published draft guidance has recommended against using Tukysa on the National Health Service.

Health technology assessment (HTA) body NICE has preliminarily recommended against the use of Seagen’s Tukysa (tucatinib), in combination with trastuzumab and capecitabine, as a third-line treatment for advanced breast cancer because it does not believe that the treatment is good value for money.

While NICE called Tukysa “a promising, innovative new treatment,” it said that the cost-effectiveness estimates for the combination product were...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Market Access

More from Pink Sheet

Manufacturers Can Keep Their Shoes On: FDA PreCheck To Streamline US Facility Applications

 
• By Derrick Gingery

The program would allow early interactions with FDA staff to speed construction and approval of pharmaceutical manufacturing facilities in the US, but will staff be available?

Off-Patent Drugs Get UK Spotlight, But Picture Is Still ‘Nuanced’

 
• By Urtė Fultinavičiūtė

The importance of generic and biosimilar medicines is being recognized by the UK government for the first time. However, Mark Samuels, CEO of Medicines UK, the trade body representing the off-patent industry, says companies are still face multiple hurdles in the market.

MHRA Investigates GLP-1 And Pancreatitis Genetic Link In Personalized Medicine Push

 
• By Eliza Slawther

The UK drug regulator is collecting data to establish whether patients who are hospitalized for acute pancreatitis after taking a GLP-1 drug have a genetic predisposition to this side effect. If a “clear link” is found, the MHRA would consider regulatory action.